214 related articles for article (PubMed ID: 20528149)
1. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.
Gordon N; Kleinerman ES
J Aerosol Med Pulm Drug Deliv; 2010 Aug; 23(4):189-96. PubMed ID: 20528149
[TBL] [Abstract][Full Text] [Related]
2. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases.
Gordon N; Kleinerman ES
Cancer Treat Res; 2009; 152():497-508. PubMed ID: 20213411
[TBL] [Abstract][Full Text] [Related]
3. The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.
Koshkina N; Yang Y; Kleinerman ES
Adv Exp Med Biol; 2020; 1258():177-187. PubMed ID: 32767242
[TBL] [Abstract][Full Text] [Related]
4. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine.
Gordon N; Koshkina NV; Jia SF; Khanna C; Mendoza A; Worth LL; Kleinerman ES
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4503-10. PubMed ID: 17671136
[TBL] [Abstract][Full Text] [Related]
5. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases.
Koshkina NV; Kleinerman ES
Int J Cancer; 2005 Sep; 116(3):458-63. PubMed ID: 15800950
[TBL] [Abstract][Full Text] [Related]
6. Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases.
Huang G; Nishimoto K; Yang Y; Kleinerman ES
Adv Exp Med Biol; 2014; 804():203-17. PubMed ID: 24924176
[TBL] [Abstract][Full Text] [Related]
7. Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs.
Rodriguez CO; Crabbs TA; Wilson DW; Cannan VA; Skorupski KA; Gordon N; Koshkina N; Kleinerman E; Anderson PM
J Aerosol Med Pulm Drug Deliv; 2010 Aug; 23(4):197-206. PubMed ID: 19803732
[TBL] [Abstract][Full Text] [Related]
8. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma.
Koshkina NV; Khanna C; Mendoza A; Guan H; DeLauter L; Kleinerman ES
Mol Cancer Res; 2007 Oct; 5(10):991-9. PubMed ID: 17951400
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases.
Rao-Bindal K; Koshkina NV; Stewart J; Kleinerman ES
Curr Cancer Drug Targets; 2013 May; 13(4):411-22. PubMed ID: 23410027
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing.
Siena L; Pace E; Ferraro M; Di Sano C; Melis M; Profita M; Spatafora M; Gjomarkaj M
Immunology; 2014 Feb; 141(2):242-55. PubMed ID: 24128051
[TBL] [Abstract][Full Text] [Related]
11. Eradication of osteosarcoma lung metastasis using intranasal gemcitabine.
Jia SF; Worth LL; Turan M; Duan Xp XP; Kleinerman ES
Anticancer Drugs; 2002 Feb; 13(2):155-61. PubMed ID: 11901308
[TBL] [Abstract][Full Text] [Related]
12. miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression.
Huang G; Nishimoto K; Zhou Z; Hughes D; Kleinerman ES
Cancer Res; 2012 Feb; 72(4):908-16. PubMed ID: 22186140
[TBL] [Abstract][Full Text] [Related]
13. Fas expression in lung metastasis from osteosarcoma patients.
Gordon N; Arndt CA; Hawkins DS; Doherty DK; Inwards CY; Munsell MF; Stewart J; Koshkina NV; Kleinerman ES
J Pediatr Hematol Oncol; 2005 Nov; 27(11):611-5. PubMed ID: 16282894
[TBL] [Abstract][Full Text] [Related]
14. Autophagy in osteosarcoma.
O'Farrill JS; Gordon N
Adv Exp Med Biol; 2014; 804():147-60. PubMed ID: 24924173
[TBL] [Abstract][Full Text] [Related]
15. Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts.
Rao-Bindal K; Rao CK; Yu L; Kleinerman ES
Pediatr Blood Cancer; 2013 Apr; 60(4):575-9. PubMed ID: 23255321
[TBL] [Abstract][Full Text] [Related]
16. Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases.
Koshkina NV; Rao-Bindal K; Kleinerman ES
Cancer; 2011 Aug; 117(15):3457-67. PubMed ID: 21287529
[TBL] [Abstract][Full Text] [Related]
17. The Histone Deacetylase Inhibitor Entinostat/Syndax 275 in Osteosarcoma.
Kiany S; Harrison D; Gordon N
Adv Exp Med Biol; 2020; 1257():75-83. PubMed ID: 32483732
[TBL] [Abstract][Full Text] [Related]
18. VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells.
Jia SF; Guan H; Duan X; Kleinerman ES
J Exp Ther Oncol; 2008; 7(2):89-97. PubMed ID: 18771083
[TBL] [Abstract][Full Text] [Related]
19. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells.
Lafleur EA; Koshkina NV; Stewart J; Jia SF; Worth LL; Duan X; Kleinerman ES
Clin Cancer Res; 2004 Dec; 10(23):8114-9. PubMed ID: 15585647
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway.
Ferreira CG; Tolis C; Span SW; Peters GJ; van Lopik T; Kummer AJ; Pinedo HM; Giaccone G
Clin Cancer Res; 2000 Jan; 6(1):203-12. PubMed ID: 10656451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
